This is a working overview of melanocortin receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-12. Anything still debated is marked as such rather than presented as settled.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Alpha-MSH analogue with a lactam ring |
| Molecular formula | C50H69N15O9 | Commonly cited value for the neutral peptide |
| Molecular weight | 1024.18 g/mol | Calculated for the free molecule |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water, DMSO and ethanol | Dissolution in pure water is often slow |
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Burroughs and others claimed that it was a "metabolic regulator" with a restorative dimension to a damaged or dysfunctional dopaminergic system. Despite anecdotal evidence that this offers a plausible route to an abstinence-based mode, no clinical trials have ever tested this hypothesis. A recent study indicates that apomorphine might be a suitable marker for assessing central dopamine system alterations associated with chronic heroin consumption. There is, however, no clinical evidence that apomorphine is an effective and safe treatment regimen for opiate addiction.
In this application, Ion-exchange resins are used to replace the magnesium and calcium ions found in hard water with sodium ions. When the resin is fresh, it contains sodium ions at its active sites. When in contact with a solution containing magnesium and calcium ions (but a low concentration of sodium ions), the magnesium and calcium ions preferentially migrate out of solution to the active sites on the resin, being replaced in solution by sodium ions. This process reaches equilibrium with a much lower concentration of magnesium and calcium ions in solution than was started with.
Birds excrete their nitrogenous wastes as uric acid in the form of a paste. Although this process is metabolically more expensive, it allows more efficient water retention and it can be stored more easily in the egg. Many avian species, especially seabirds, can also excrete salt via specialized nasal salt glands, the saline solution leaving through nostrils in the beak.
== Side effects == The most common side effects include lymphadenopathy (swollen lymph nodes), itching, pain, oedema, and bleeding (for example in the form of bruises or ecchymoses). Allergic reactions are seen in less than 1% of patients. In Peyronie's disease, potential side effects include corporal rupture (penile fracture) or other serious penile injury.
Sources: en.wikipedia.org
In January 2013, the FDA reported shortages of some, but not all, forms of doxycycline "caused by increased demand and manufacturing issues". Companies involved included an unnamed major generics manufacturer that ceased production in February 2013, Teva (which ceased production in May 2013), Mylan, Actavis, and Hikma Pharmaceuticals. The shortage came at a particularly bad time, since there were also shortages of an alternative antibiotic, tetracycline, at the same time. The market price for doxycycline dramatically increased in the United States in 2013 and early 2014 (from $20 to over $1800 for a bottle of 500 tablets), before decreasing again.
=== Analogues === Although several related compounds are disclosed in the original patent, no activity data are provided and it was unclear whether these share tianeptine's unique pharmacological effects. More recent structure-activity relationship studies have since been conducted, providing some further insight on μ-opioid, δ-opioid, and pharmacokinetic activity. Derivatives where the aromatic chlorine substituent is replaced by bromine, iodine or methylthio, and/or the heptanoic acid tail is varied in length or replaced with other groups such as 3-methoxypropyl, show similar or increased opioid receptor activity relative to tianeptine, with up to 13x higher potency than tianeptine itself. Amineptine, the most closely related drug to have been widely studied, is a dopamine reuptake inhibitor with no significant effect on serotonin levels, nor opioid agonist activity. Tianeptinaline and tianeptinostat, analogues of tianeptine, are potent histone deacetylase (HDAC) inhibitors.
Relative humidity The relative humidity of air is defined as the partial pressure of water vapour divided by the saturated vapour pressure at the same temperature and total pressure. If the temperature is kept constant, lower relative humidities result in higher drying rates due to the increased moisture gradient in wood, resulting from the reduction of the moisture content in the surface layers when the relative humidity of air is reduced. The relative humidity is usually expressed on a percentage basis. For drying, the other essential parameter related to relative humidity is the absolute humidity, which is the mass of water vapour per unit mass of dry air (kg of water per kg of dry air). However, its influenced by the amount of water in the heated air. Air circulation rate Drying time and timber quality depend on the air velocity and its uniform circulation. At a constant temperature and relative humidity, the highest possible drying rate is obtained by rapid circulation of air across the surface of wood, giving rapid removal of moisture evaporating from the wood. However, a higher drying rate is not always desirable, particularly for impermeable hardwoods, because higher drying rates develop greater stresses that may cause the timber to crack or distort. At very low fan speeds, less than 1 m/s, the air flow through the stack is often laminar flow, and the heat transfer between the timber surface and the moving air stream is not particularly effective.
== Career == Zaffaroni joined Syntex, then a small chemical company in Mexico, as a biochemist in 1951. He participated in turning Syntex into a major multinational pharmaceutical company, moving it to Palo Alto, California. He was appointed president of the U.S. subsidiary in 1962. In 1968, he founded ALZA, a syllabic abbreviation of his name, to develop medical treatments through controlled drug delivery. He modeled new delivery systems after the processes discovered in endocrinology – where glands deliver very small amounts of hormones but have a tremendous effect –. ALZA's first controlled drug delivery product was used to treat glaucoma. Other products that incorporated Zaffaroni's drug delivery technologies include Glucotrol, for non insulin-dependent diabetes; Duragesic, for management of severe chronic pain; NicoDerm CQ, for smoking cessation; and Transderm-Scop, to prevent nausea and vomiting associated with motion sickness. In 1980, Zaffaroni established DNAX, a developer of macromolecular products that combines the technologies of genetic engineering and immunobiology. In 1988 he co-founded Affymax, specializing in combinatorial chemistry to reduce the cost and time of identifying new medicines. In 1991 he co-founded Affymetrix, specializing in using genetics for developing new medicine. He was also involved in the creation of Perlegen Sciences, an Affymetrix spin-off which works on finding genetic causes of disease. In 1994, he founded Symyx Technologies, a company dedicated to utilizing combinatorial chemistry technologies.
A representative of the Swedish Olympic Committee said, "I see it as ill-conceived, short-sighted and foolhardy and something other than sport." The UK Anti-Doping organisation said in a statement that "UKAD's mission is to protect sport from doping cheats. There is no place in sport for performance enhancing drugs, nor the Enhanced Games." Travis Tygart, CEO of the United States Anti-Doping Agency (USADA), said: "farcical … likely illegal in many [US] states" and "a dangerous clown show, not real sport." Rahul Gupta, director of the Office of National Drug Control Policy, stated that the Biden administration had deep concerns regarding TEG. The China Anti-Doping Agency (CHINADA) stated that it is in "firm opposition to any attempt to portray doping as so-called scientific advancements, and calls on the global sports community to stand united in rejecting the Enhanced Games." TEG filed a lawsuit in the United States District Court for the Southern District of New York in Manhattan against several sporting bodies in August 2025, including World Aquatics and WADA. The allegation is that these organizations are violating anti-trust laws by preventing athletes from competing in TEG. United States District Judge Jesse Furman dismissed the lawsuit in a 33-page order in November 2025. The organization chose not to refile the lawsuit within the 30-day deadline, and the court closed the case.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.
No national medicines agency has approved melanotan-2 for clinical use. Afamelanotide, a related but distinct peptide, holds a marketing authorisation in the European Union for a rare photosensitivity disorder. Melanotan-2 itself is handled as a laboratory chemical.
Its broad activity across melanocortin receptors makes it a tool for probing pigmentation, appetite and vascular signalling. Early trials recorded skin darkening and other effects that were not the original focus of the work. Those observations generated hypotheses that later studies have examined.
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.